Ligand Pharmaceuticals (LGND) Receivables (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Receivables data on file, last reported at $53.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 38.69% year-over-year to $53.4 million; the trailing twelve-month figure through Mar 2026 stood at $53.4 million (up 38.69% YoY), and the FY2025 full-year result was $59.6 million, up 55.31% from the prior year.
• Receivables slipped to $53.4 million in Q1 2026, from $59.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $65.2 million in Q3 2022 to a low of $28.0 million in Q2 2023.
• A 5-year average of $42.0 million and a median of $38.4 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables sank 64.4% in 2022 and jumped 67.73% in 2025, its largest moves.
• Tracing LGND's Receivables over 5 years: stood at $30.4 million in 2022, then climbed by 8.19% to $32.9 million in 2023, then rose by 16.58% to $38.4 million in 2024, then soared by 55.31% to $59.6 million in 2025, then dropped by 10.43% to $53.4 million in 2026.
• Business Quant data shows LGND's Receivables at $53.4 million in Q1 2026, $59.6 million in Q4 2025, and $57.6 million in Q3 2025.